GlobeNewswire All Public CompaniesQwen · 实盘不做把握 1/10不做原因:不是事件
北京时间·🕒 发布 20:05:00·⟳ 抓取 20:06:54·⚡ 决策 08-27 20:09:17 +2m23s·61.0 天前
Harmony Biosciences 宣布管理层将参加 2026 年 Cantor 全球医疗健康会议炉边对话
这是一份例行的会议参加通知（fireside chat participation），全文不含任何新的临床数据、监管进展、财务指引、订单、合作或战略信息。会议参加公告是上市公司最常见的 IR 例行发布，不构成任何方向的交易催化，Web/KB/行情研究均无法改变'不做'的结论。
📄 原文GlobeNewswire All Public Companies↗ 原文
Harmony Biosciences to Participate in 2026 Cantor Global Healthcare Conference
PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today annou…
不做 Harmony Biosciences（HRMY.US）
例行会议参加通知，不含任何新增业务信息（无临床数据、无管线进展、无财务指引、无合作/订单），不构成交易催化，方向不明且无 edge
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
Harmony Biosciences 发布新闻稿宣布管理层将于 9 月 10 日参加 Cantor 全球医疗健康会议炉边对话。全文仅包含会议时间、地点和网络直播链接，无任何新增业务事实。此类公告在美股市场每日大量出现，不对股价产生任何方向性影响，不构成可交易事件。
🔎 新鲜度:最早出现 2026-08-27 · 扩散 low · price-in 风险 low ↗
先例如何影响了这次决策
对本次决策的影响:无——本事件不构成催化，先例研究不适用
方向:不适用——会议参加通知不构成事件，无需先例
涨幅量级:不适用
形态:不适用
原文全文
展开原文 · 1,463 字
PLYMOUTH MEETING, Pa., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York, N.Y., on Thursday, September 10, 2026, at 10:20 a.m., E.T.
A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at
https://ir.harmonybiosciences.com/
.
About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit
www.harmonybiosciences.com
.
Harmony Biosciences Investor Contact:
Brennan Doyle
484-566-3685
bdoyle@harmonybiosciences.com
Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com
A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at
https://ir.harmonybiosciences.com/
.
About Harmony Biosciences
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit
www.harmonybiosciences.com
.
Harmony Biosciences Investor Contact:
Brennan Doyle
484-566-3685
bdoyle@harmonybiosciences.com
Harmony Biosciences Media Contact:
Cate McCanless
202-641-6086
cmccanless@harmonybiosciences.com
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。